Post Profile






KEYNOTE-040 evaluates pembrolizumab in head and neck cancer

LUGANO-MADRID, 11 September, 2017 - Immunotherapy with the checkpoint inhibitor pembrolizumab may be a better option than standard treatments for patients whose head and neck cancer has spread, or recurred after an initial round of chemotherapy, according to results of the Keynote-040 trial presented at the ESMO 2017 Congress in Madrid. (1)
read more

share

Related Posts


Cancers Evade Immunotherapy by 'Discarding the Evidence' of Tumor-Specific Mutations

Health : Newswise Medical News

Results of an initial study of tumors from patients with lung cancer or head and neck cancer suggest that the widespread acquired resistance to immunotherapy drugs known as checkpoint inhibitors may be due to the elimination of cert...

Researchers Find Immunotherapy Treatments Better for Advanced Skin Cancer

Health : Newswise Medical News

The team evaluated 15 randomized controlled trials published between 2011 and 2015, assessing the benefits and harms of targeted or immune checkpoint inhibitors in 6,662 patients with cancer that had spread to the lymph nodes and su...

Some head and neck cancer patients benefit from continued checkpoint inhibitor treatment

Health : EurekAlert: Health

(Dana-Farber Cancer Institute) New research suggests that some patients with head and neck cancers can benefit by continuing treatment with an immunotherapy drug after their tumors show signs of enlargement according to investigator...

Mature results favor pembrolizumab as second-line treatment for bladder cancer

Health : EurekAlert: Health

(European Society for Medical Oncology) Mature results from the KEYNOTE-045 trial to be presented today at the ESMO 2017 Congress in Madrid have confirmed significantly longer survival in patients with advanced urothelial cancer who...

KEYNOTE-040 evaluates pembrolizumab in head and neck cancer

Health : EurekAlert: Health

(European Society for Medical Oncology) Immunotherapy with the checkpoint inhibitor pembrolizumab may be a better option than standard treatments for patients whose head and neck cancer has spread, or recurred after an initial round...

Comments


Copyright © 2016 Regator, LLC